Safety of ocriplasmin intravitreal injection in patients with focal vitreomacular adhesion with exudative age-related macular degeneration.

Trial Profile

Safety of ocriplasmin intravitreal injection in patients with focal vitreomacular adhesion with exudative age-related macular degeneration.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2015

At a glance

  • Drugs Ocriplasmin (Primary)
  • Indications Age-related macular degeneration; Retinal disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2015 New trial record
    • 01 Apr 2015 Results published in the Ophthalmology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top